Objective. While infection burden is high among patients with systemic lupus erythematosus (SLE), there is uncertainty about whether infection rates differ by immunosuppressive drug regimens. We undertook this study to compare infection rates among SLE patients newly initiating immunosuppressive therapy with mycophenolate mofetil (MMF), azathioprine (AZA), or cyclophosphamide (CYC).
reported data (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . In addition, RCTs are generally underpowered to estimate with adequate precision the comparative risk of adverse events such as infections.
In rheumatoid arthritis, large, population-based comparative safety studies have demonstrated elevated risks of serious infections associated with use of specific immunosuppressive medications (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . Our prior work in the Medicaid SLE patient population highlighted an increased risk of serious infections among individuals who received immunosuppressive medications compared to those who did not (29) . Meta-analyses comparing the efficacy and safety of immunosuppressive medications in SLE patients from pooled RCT data reported similar numbers of infections for the drugs assessed (30) (31) (32) . However, serious infections were rare, and the meta-analyses were limited by the original RCTs' inclusion and exclusion criteria and, often, short duration of follow-up. However, the comparative risk of infection across individual immunosuppressive drugs among patients with SLE has not been previously investigated in a population-based cohort.
In addition to hydroxychloroquine and corticosteroids, mycophenolate mofetil (MMF), azathioprine (AZA), and cyclophosphamide (CYC) are the most commonly used medications to treat patients with moderate-tosevere SLE. We aimed to assess whether there were any differences in the rates of serious infections among SLE patients initiating MMF compared to AZA and among those initiating MMF compared to CYC in a nationwide longitudinal cohort. We chose these comparisons because of the relatively interchangeable use of CYC and MMF for induction therapy and MMF and AZA for maintenance therapy among patients with severe SLE. Specifically, multiple meta-analyses of RCTs have found minimal if any conclusive differences between MMF and CYC for induction of remission and between MMF and AZA for maintenance of remission among patients with proliferative lupus nephritis (30, (33) (34) (35) (36) . In addition, the most recent American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis (37) support interchangeable use of MMF and CYC for induction therapy and MMF and AZA for maintenance therapy (38, 39) . However, given the lack of head-to-head studies of the comparative infection rates associated with these different immunosuppressive medications, it remains unclear which drug may confer increased risk, and no information is currently available to inform treatment choice.
PATIENTS AND METHODS
Data source. We used insurance claims data from the Medicaid Analytic eXtract (MAX) database for Medicaid enrollees from the 29 most populated US states, from January 1, 2000 through December 31, 2010 . Medicaid is the largest public health insurance program in the US, covering more than 60 million racially and ethnically diverse, low-income individuals nationwide. The MAX database includes demographic information and longitudinal claims for covered health care services, including the corresponding diagnosis and procedure codes and pharmacy dispensing details for all beneficiaries. De-identified data were obtained through a Data Use Agreement with the Centers for Medicare and Medicaid Services, and an Institutional Review Board of Brigham and Women's Hospital approved this study.
Study cohort selection and exposure definition. Our cohort included adults ages 18-65 years, with prevalent SLE defined by $2 International Classification of Diseases, Ninth Revision (ICD-9) codes for SLE (710.0) separated by $30 days. We then selected patients with a new prescription for MMF, AZA, or oral or intravenous CYC within 365 days of one of the ICD-9 codes for SLE, with continuous enrollment in Medicaid for the 6 months prior to the date of first prescription dispensing (the index date). For CYC, we additionally included Healthcare Common Procedure Coding System J-codes for non-orally administered drugs and Current Procedural Terminology (CPT) codes for infusions. Patients were required to have no documented use of the drug of interest or the direct comparator drug during the 6 months prior to the index date, and we excluded patients with human immunodeficiency virus/acquired immunodeficiency syndrome or organ or bone marrow transplantation. We additionally excluded patients who used tacrolimus because of significant imbalance between the comparator groups.
Outcome definition. The primary outcome of interest was first serious infection, defined as a hospital discharge diagnosis ICD-9 code (in any position) for bacterial infection (bacteremia, cellulitis, pneumonia, pyelonephritis, osteomyelitis, septic arthritis, endocarditis), fungal infection (aspergillosis, cryptococcosis, histoplasmosis, pneumocystosis), viral infection (herpes zoster, cytomegalovirus, varicella zoster, influenza), and mycobacterial infection (tuberculosis, nontuberculous mycobacteria). A validation study has demonstrated a mean positive predictive value (PPV) of 80% for bacterial infections (40) . The mean PPV for opportunistic infections was 76% and included discharge diagnosis ICD-9 codes for tuberculosis (PPV 77%), atypical mycobacterial infection (PPV 70%), cryptococcosis (PPV 100%), and aspergillosis (67%) (40) . We excluded candidiasis based on findings from this validation study (PPV 20%), and we excluded meningitis and encephalitis due to an inability to distinguish between infectious and SLE-related etiologies (29, 40) . We restricted our analyses to the most serious infections; therefore, we did not include infection diagnosis codes from outpatient encounters. We excluded common nosocomial infections, including urinary tract and surgical site infections, to focus on those that were more likely to result in hospitalization than to occur from hospitalization. We additionally examined only primary discharge diagnosis of serious infection to further restrict our definition to infections that were most likely the cause of the hospitalization. In secondary analyses we assessed all hospitalized infections rather than restricting to the first infection. To accomplish this we examined all serious hospitalized infections separated by .30 days to minimize counting of readmissions for the same infection. We also examined all-cause mortality using Social Security Death Index files linked to the MAX database. Cause of death information was not available.
Covariates. We assessed patient characteristics and other covariates during the 6 months prior to and including the index date. Demographic information included age at the (42) . We used the SLE-specific risk adjustment index, which includes comorbidities relevant to SLE patients shown to be associated with all-cause mortality among US Medicaid SLE patients (43, 44) . We defined lupus nephritis as $1 ICD-9 code for glomerulonephritis, proteinuria, or kidney failure on or after the SLE diagnosis. In addition to the SLE-specific risk adjustment index, we included diabetes mellitus, chronic kidney disease (using codes for renal disease or dialysis during the baseline period independent of the timing of the SLE code), alcoholism, smoking, obesity, hepatitis, chronic lung disease, and malignancies.
We assessed the total number of medications prescribed and use of the following medications during the baseline 6-month period: hydroxychloroquine, chloroquine, sulfasalazine, methotrexate, leflunomide, cyclosporine, anti-tumor necrosis factor agents, nonsteroidal antiinflammatory drugs, and corticosteroids. We included prior baseline use of CYC in the MMF versus AZA cohort and prior baseline use of AZA in the MMF versus CYC cohort. In addition, we calculated the cumulative prednisone-equivalent corticosteroid dose dispensed during the 60 days prior to and including the index date and categorized the mean prednisone-equivalent dose as 0-5 mg/day, .5-15 mg/day, or .15 mg/day.
To include health care utilization, we used number of outpatient, inpatient, and emergency department visits and number of hospitalization days. As a proxy for disease severity, we used the number of SLE-related laboratory tests. We addressed preventive care by including vaccinations (influenza and pneumococcal) determined by $1 CPT code and pneumocystosis prophylaxis using dispensing data for trimethoprim/sulfamethoxazole, atovaquone, dapsone, or pentamidine.
Statistical analysis. We assessed baseline characteristics of the study cohort with chi-square tests, Fisher's exact tests, Wilcoxon rank sum tests, Mann-Whitney U tests, and t-tests. To minimize confounding by indication, we used a propensity score matching method. Multivariable logistic regression models were constructed to estimate the respective probabilities of initiating MMF versus AZA and of initiating MMF versus CYC conditional on observed baseline covariates. We included all baseline demographic factors, comorbidities, medications, health care utilization factors, and the SLE-specific risk adjustment index, in addition to calendar year. We used nearest neighbor matching within a caliper of 0.025 on the propensity score at a fixed ratio of 1:1 for both the MMF versus AZA and MMF versus CYC comparisons (45, 46) .
In primary analyses for both drug pair comparisons, we determined rates of first serious infection and of all-cause mortality over 6-and 12-month periods beginning the day after the index date. The goal was to simulate an intent-to-treat (ITT) analysis at 6 and 12 months. We performed ITT analyses paralleling clinical trials to reduce the bias introduced by excluding nonadherers. Patients were censored at death, disenrollment from Medicaid, or end of follow-up. We calculated incidence rates for serious infections with 95% confidence intervals (95% CIs) for the propensity score-matched pairs of MMF versus AZA and MMF versus CYC new users. We used Cox proportional hazards models to estimate hazard ratios (HRs) with 95% CIs of first serious infection between the propensity scorematched groups. Due to a residual imbalance in cumulative corticosteroid dose in both propensity score-matched drug comparisons, we additionally adjusted for cumulative corticosteroid dose in the 60 days preceding and including the index date in all models. We tested the proportional hazards assumption using an interaction term between the drug exposure and the log of follow-up time, and we did not detect any such violations (47) .
In secondary analyses, we examined incidence rates and incidence rate ratios (IRRs) with 95% CIs of all serious infections occurring after the index date using Poisson regression models. To assess potential differences in infection rates between oral and intravenous CYC therapy, we used Cox models to separately examine our outcome among propensity score-matched MMF versus oral CYC and MMF versus intravenous CYC users. We also conducted as-treated analyses for MMF versus AZA and for MMF versus CYC. For the as-treated MMF versus CYC comparison, we examined oral and intravenous CYC separately as well as combined. For the MMF versus AZA and the MMF versus oral CYC comparisons, we assessed rates of first serious infection beginning the day following the index date and censored at drug discontinuation, gaps greater than 30 days, switch to the comparator drug, death, disenrollment from Medicaid, or end of follow-up. Our ability to conduct the as-treated MMF versus intravenous CYC comparison was limited by differences in protocols regarding frequency of use. We used the same criteria as for the oral comparison; however, we censored at gaps greater than 40 days rather than 30 days to allow for 10 days leeway in scheduling of monthly infusions.
We performed additional secondary analyses using matching weights instead of propensity scores both for the MMF versus AZA comparison and for the MMF versus CYC comparison. Matching weights allows for the preservation of sample size when potential paired comparators may be limited, and it may result in more efficient estimation and more precise variance calculations (48) . We used matching weights and weighted Cox models to compare serious infections and death in ITT and as-treated analyses. We conducted all analyses using SAS software, version 9.3 (SAS Institute).
RESULTS
Cohort selection and patient characteristics. Prior to matching, we identified 2,764 MMF new users and 3,513 AZA new users who met our prespecified inclusion and exclusion criteria (see Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.39849/abstract). In the unmatched cohort, while demographic factors were similar, compared to AZA new users, MMF new users had higher SLE-specific risk adjustment indices, a greater burden of kidney disease and specifically lupus nephritis, were taking more medications on average, received more preventive care, and had greater health care utilization. From this cohort, we identified 1,350 propensity score-matched pairs of MMF and AZA initiators (Figure 1 ). The mean 6 SD age was 34.8 6 11.6 years among MMF users and 34.5 6 11.5 years among AZA users. The mean 6 SD follow-up time was 3.7 6 3.0 years among MMF users and 4.0 6 3.0 years among AZA users ( Table  1) . The overall C statistic was 0.85 for MMF versus AZA. There were no statistically significant differences between any of the characteristics including comorbidities, medication use, preventive care, or health care utilization. However, cumulative corticosteroid dose was higher in the AZA group.
Prior to matching, for our MMF versus CYC comparison, we identified 2,982 MMF new users and 735 CYC new users (see Supplementary Table 1 , http://onlinelibrary.wiley. com/doi/10.1002/art.39849/abstract). Compared to MMF new users, CYC new users had higher SLE-specific risk adjustment indices, less frequent hydroxychloroquine use, increased hospitalizations, and higher median cumulative prednisone doses. We then identified 674 propensity scorematched pairs of MMF and CYC initiators. The mean 6 SD age was 35.9 6 12.1 years among MMF users and 35.7 6 12.2 years among CYC users. The mean 6 SD follow-up time was 4.3 6 3.3 years among MMF users and 4.1 6 3.1 years among CYC users (Table 1) . A total of 364 MMF users were common to both the MMF versus AZA cohort and the MMF versus CYC cohort. Among the 674 CYC users, 314 (46.6%) received oral therapy and 360 (53.4%) received intravenous therapy. The only statistically significant difference was a higher cumulative corticosteroid dose among CYC initiators; therefore, we additionally adjusted for this variable in our analyses. The overall C statistic was 0.78 for MMF versus CYC. Overall, the MMF versus CYC and MMF versus AZA cohorts had similar distributions of demographic characteristics, including age and race/ethnicity. However, the MMF versus CYC cohort had greater comorbidities (particularly lupus nephritis), a higher SLE-specific risk adjustment index, increased medication use and median corticosteroid dose, and slightly greater health care utilization. , and P values for all comparisons were greater than 0.05 with the exception of corticosteroid dose. In accordance with federal policies concerning data privacy, cell sizes ,11 were not reported (NR). Alcoholism, substance abuse, and other immunosuppressive drugs were also included in the propensity score but were excluded from the table as one or more groups were not reported. IQR 5 interquartile range; NA 5 not applicable; NSAIDs 5 nonsteroidal antiinflammatory drugs; COX-2 5 cyclooxygenase 2. † Based on a composite index of US Census variables. ‡ Defined as $1 International Classification of Diseases, Ninth Revision code for glomerulonephritis, proteinuria, or renal failure on or after diagnosis of systemic lupus erythematosus (SLE). § The baseline mean number of SLE-related laboratory tests was assessed and was balanced between the 2 groups. ¶ Determined during the 60 days prior to and including the index date, based on prednisone-equivalent doses. # Includes trimethoprim/sulfamethoxazole, atovaquone, dapsone, and pentamidine.
SERIOUS INFECTION RATES IN SLE, BY IMMUNOSUPPRESSIVE THERAPY RECEIVED 391
We additionally examined median daily prednisoneequivalent dose from the index date until the outcome of interest (first serious infection) for each of the drug comparisons. For the MMF versus AZA cohort, the median daily prednisone-equivalent dose was 4.10 mg for MMF new users and 4.02 mg for AZA new users. For the MMF versus CYC comparison, the median daily prednisone-equivalent dose was 4.60 mg for MMF new users and 5.05 mg for CYC new users. We did not additionally adjust for corticosteroid use following the index date for 3 central reasons. First, the median daily dose was similar across the comparator drugs. Second, we adjusted for baseline corticosteroid use both through inclusion in the propensity scores and additionally in our Cox proportional hazards models. Third, corticosteroid use following the index date may be an intermediate variable that lies on the causal pathway between the drug of interest and serious infections, and adjusting for this potential mediator would bias our estimate of risk associated with the drugs of interest (49, 50) .
Serious infection rates. MMF versus AZA. In the primary 6-month ITT analysis, the incidence rate of first hospitalized infection per 100 person-years was 14.6 (95% CI 11.6-17.6) among MMF new users and 15.2 (95% CI 12.1-18.3) among AZA new users (Table 2) . More than 90% of infections in both MMF and AZA new users were bacterial. There was no significant difference between the 2 groups in the rate of infection (HR 0.99 [95% CI 0.74-1.32]). Similarly, we found no difference in infection rates in the 12-month ITT analysis, or when we only considered hospitalizations for which infection was the primary discharge diagnosis.
In secondary analyses including all serious infections following the index date, the incidence rate of all serious infections per 100 person-years was 17.4 (95% CI 14.1-20.6) among MMF users and 17.8 (95% CI 14.5-21.0) among AZA users (Table 3) ; these rates did not differ (IRR 1.01 [95% CI 0.85-1.20]). In as-treated analyses, follow-up time was similar to that in the 6-month ITT analysis, and results were consistent with the primary analyses (Table 4 ). Similar to the MMF versus AZA comparison, .90% of infections among both MMF and CYC users were bacterial. When we considered CYC as the reference exposure, there was no significant difference in rates (HR 0.95 [95% CI 0.69-1.32]). We obtained parallel results without any significant differences with our 12-month ITT analyses. Similarly, we found no difference when we only considered hospitalizations for which infection was the primary discharge diagnosis (HR 0.98 [95% CI 0.65-1.47]).
In secondary analyses of all serious infections, the incidence rate per 100 person-years was 28.9 (95% CI 23.0-34.8) among MMF users and 29.5 (95% CI 23.6-35.4) among CYC users (Table 5) , again without any significant difference between these groups (IRR 0.94 [95% CI 0.74-1.19]). To understand differences in risk of infection by route of administration of CYC, we separately compared matched pairs of MMF and intravenous CYC users and MMF and oral CYC users. While the incidence rate of serious infections was higher among oral CYC users than among intravenous CYC users, the 95% CIs overlapped (see Supplementary Table 4A , http://onlinelibrary.wiley. com/doi/10.1002/art.39849/abstract). The HRs for both MMF versus CYC comparisons were not statistically significant, and the 95% CIs overlapped, suggesting no difference in serious infection risk (see Supplementary Tables 4B  and C , http://onlinelibrary.wiley.com/doi/10.1002/art.39849/ abstract). As-treated analyses also showed no difference in serious infection risk for MMF versus oral CYC or versus (Table 4 ). In 12-month ITT analyses for both comparator groups, and in astreated analyses, we similarly found no significant differences in mortality by drug category. Secondary analyses using matching weights supported these findings of no statistically significant differences in mortality for either comparison (see Supplementary Tables 3 and 6 , http:// onlinelibrary.wiley.com/doi/10.1002/art.39849/abstract).
DISCUSSION
In a large, national comparative safety study of Medicaid beneficiaries with SLE, we found no significant differences in the respective rates of serious infections or mortality among new users of AZA or CYC when compared with otherwise similar patients who initiated treatment with MMF. These results are consistent with those of meta-analyses of RCTs that have suggested that the safety of MMF versus AZA and of MMF versus CYC in terms of risk of serious infection may be comparable (38, 39) . However, those meta-analyses had pooled studies focused on treatment efficacy, and thus the numbers of adverse events were small and difficult to compare meaningfully between groups. Similarly, individual clinical trials of MMF versus AZA and of MMF versus CYC have demonstrated variability in serious infection rates between treatment arms, but the actual numbers of infections were small, and therefore differences may have represented Type I errors (17) .
Cohort studies have shown elevated rates of serious infections among patients receiving CYC and an association of certain infections such as herpes zoster with MMF use (10, 11) . Comparisons of adverse events, as extrapolated from meta-analyses, have shown similar rates of infection and gastrointestinal upset between MMF and AZA users, but increased leukopenia among AZA users (34) . Similarly, leukopenia was found to be more common among CYC users than among MMF users in a meta-analysis of induction therapy (31) .
However, even with these pooled meta-analyses, adverse events were infrequent, making comparisons challenging to interpret. In addition, inclusion and exclusion criteria from the RCTs used in these meta-analyses limit the overall generalizability of the findings.
In the Medicaid population, which has previously been shown to have a significant burden of SLE and of adverse outcomes, we found high rates of serious infections associated with use of all 3 of the immunosuppressive medications examined (44, 51) . The serious infection incidence rates observed for the MMF versus AZA cohort were slightly higher but were consistent with those that we reported in a previous study among overall Medicaid beneficiaries with SLE (29). The incidence rates for the MMF versus CYC cohort were comparable to those that we observed among Medicaid beneficiaries with lupus nephritis. Therefore, while no differences were observed in our analyses between the specific immunosuppressive drug comparisons, the high burden of serious infections among SLE patients receiving these medications overall is important to consider.
To our knowledge, this is the largest head-to-head population-based comparative effectiveness study to examine rates of infections and death associated with these commonly and often interchangeably used medications for SLE. The sample size for both drug comparisons is larger than that for any study to date, including meta-analyses of RCT data. This large sample size and the relatively long follow-up in a real-world population treated in typical care settings have enabled us to study an infrequent outcome among patients with an uncommon disease. It is still possible, however, that even with this sample size we were underpowered to detect more subtle differences in infection risk between the drugs. However, in secondary analyses using matching weights, which allowed us to preserve a larger sample size of new users and thus improved our power, we similarly did not detect significant differences in serious infections between the drugs.
Medicaid beneficiaries are low-income individuals who have a high burden of chronic diseases and complications. This is an important population to study to better understand and treat adverse disease and drug manifestations. The overall burden of comorbidities and poor outcomes in this population is high, and therefore the absolute rates of serious infections in each group are likely higher than those in other non-Medicaid SLE populations. However, a larger effect size is also expected among groups with increased underlying risk, and therefore our finding of no significant difference when comparing each of our groups would likely hold among less vulnerable populations.
FELDMAN ET AL
In light of the lack of random treatment assignment, the design of this observational study attempts to address a number of potential biases using contemporary pharmacoepidemiologic methods. The application of a new-user design with active comparators reduces the possibility of immortal time bias and the depletion of the susceptibles and allows for appropriate adjustment of baseline confounders (52) . The time-varying nature of infections, with the possibility of highest risk at the time of initial use, is also best captured with this new-user design. The use of active comparators matched on the propensity score, simultaneously accounting for a number of covariates including sociodemographic factors, health care utilization, comorbidities, prior drug use, and preventive care, enabled us to minimize potential confounding by indication as it relates to these observed characteristics (53) . The propensity score-matched head-to-head comparisons of patients with comparable disease severity were designed to best account for the possibility that lupus severity itself could be associated with infection risk.
A challenge of using claims data is the lack of information about SLE disease activity, severity, and duration. We addressed this using proxy measures such as health care utilization and laboratory test frequency, as well as the SLE-specific risk adjustment index, and by using active comparator groups. However, residual confounding is possible from other more granular factors that could not be comprehensively assessed in this database, such as laboratory values and imaging findings. While the medications we examined may be relatively interchangeably used, there may be a preference, for example, for AZA over MMF and for MMF over CYC for women of reproductive age. Some instances of prior use of intravenous CYC may have been missed if it was administered during a hospitalization, due to potential incomplete reporting of this information during inpatient encounters. While this study used the largest sample size to date to compare overall rates of infection, it lacked power to examine specific infection subtypes as well as the effect of immunosuppressive dosages on these rates.
This study compared risk of infection in the short term (6-12 months), but further studies are needed to examine whether longer term use of these drugs alters this risk. In addition, we limited our outcome to serious infections that required hospitalization, both to improve specificity and to reduce surveillance bias. However, physicians may have had different thresholds for hospitalizing patients, and therefore some bias may remain. While the PPV of the validated codes used for serious infections is consistent with those used in most administrative studies, not all cases may be identified. While it is unlikely that this would preferentially affect individuals receiving one drug compared to another, it may lead to nondifferential bias and bias toward the null. Additionally, while we found no differences in all-cause mortality in either drug comparison, we lacked cause-of-death information and therefore were unable to examine infection-specific mortality.
This longitudinal cohort study among Medicaid beneficiaries has the potential to guide clinical decisions concerning these agents, particularly for patients with similar characteristics and moderate-to-severe SLE, who are at high risk of adverse outcomes. We demonstrated comparable rates of serious infection and death among matched MMF and AZA initiators and MMF and CYC initiators with SLE in the first 6-12 months of use. Based on these findings, concerns about differential infection risks may not need to influence physician and patient choice between MMF and AZA and between MMF and CYC, even in a population highly susceptible to adverse outcomes.
